Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze AMLX Amylyx Pharmaceuticals, Inc.. Please read: https://finlab.finance/en/setup?stock=AMLX

No install, open FinLab Studio

AMLX

Amylyx Pharmaceuticals, Inc. Healthcare As of 2026-08-26 Updated daily after market close

discounted valuation.

2 active signals
52-week adjusted-price high Top-quintile 6-month momentum
Valuation 43Quality 39Growth 19Momentum 99Risk / liquidity 47

Is Amylyx Pharmaceuticals, Inc. a buy? Fundamentals and valuation first

  • Valuation is cheaper than most peers. TTM P/E is in the 10th percentile, lower than most liquid US common stocks.

  • Recent volatility is elevated. 60-day annualized volatility is in the 95th percentile. Average 20-day dollar volume is about $127.7M.

  • Signals are active now. 52-week adjusted-price high, Top-quintile 6-month momentum currently holds; the tables below show what followed in this stock’s own history.

Watchlist

This page refreshes daily after the close. Add Amylyx Pharmaceuticals, Inc. to your watchlist to track signal changes on your next visit.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

7 historical occurrences (since 2023-01-24)
Average forward return after 52-week adjusted-price high。20-day: Win 57.1%, Sample 7, Median +4.55%, Excess +15.57%, Beat mkt rate 57.1%；60-day: Win 80%, Sample 5, Median +7.13%, Excess +18.92%, Beat mkt rate 60%

60 days after: historical avg +24.7%

20-day +18.01%
60-day +24.7%
20-day
60-day
Win
57.1%
80%
Sample
7
5
Median
+4.55%
+7.13%
Excess
+15.57%
+18.92%
Beat mkt rate
57.1%
60%

Over 5 occurrences, 60-day forward avg gained 24.7%, beat the market by 18.92 pts; win rate 80%.

Top-quintile 6-month momentum

Active · now 98.89737065309583%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

9 historical occurrences (since 2022-07-12)
Average forward return after Top-quintile 6-month momentum。20-day: Win 77.8%, Sample 9, Median +11.76%, Excess +15.35%, Beat mkt rate 66.7%；60-day: Win 85.7%, Sample 7, Median +26.8%, Excess +20.82%, Beat mkt rate 71.4%；120-day: Win 83.3%, Sample 6, Median +48.8%, Excess +69.77%, Beat mkt rate 83.3%

120 days after: historical avg +77.06%

20-day +17.72%
60-day +27.2%
120-day +77.06%
20-day
60-day
120-day
Win
77.8%
85.7%
83.3%
Sample
9
7
6
Median
+11.76%
+26.8%
+48.8%
Excess
+15.35%
+20.82%
+69.77%
Beat mkt rate
66.7%
71.4%
83.3%

Over 6 occurrences, 120-day forward avg gained 77.06%, beat the market by 69.77 pts; win rate 83.3%.

Market-wide momentum baseline

Across 97,567 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.27%, a 58.2% positive-return rate, and +2.91 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

6 times historically; 60-day forward avg +5.44%, win rate 33.3%, beating the market by -0.45 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.